Navigation Links
Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
Date:10/6/2008

ually. IBS patients fall largely into three subgroups -- constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), and mixed IBS(IBS-M) -- and 30% to 40% of these patients suffer from IBS-C. There are currently few available therapies to treat the nine million U.S. patients diagnosed with IBS-C.

About Chronic Constipation (CC)

As many as 26 million Americans suffer from CC. Patients with CC often experience hard and lumpy stools, straining during defecation, a sensation of incomplete evacuation, and fewer than three bowel movements per week. The discomfort of CC significantly affects patients' quality of life by impairing their ability to work and participate in typical daily activities.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (formerly Microbia) (http://www.ironwoodpharma.com) is an entrepreneurial pharmaceutical company dedicated to the science and art of great drugmaking. The Company is advancing several clinical candidates -- linaclotide for the treatment of irritable bowel syndrome with constipation, chronic constipation, and other functional gastrointestinal disorders; and novel, next-generation cholesterol absorption inhibitors for the treatment of hypercholesterolemia. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Microbia Precision Engineering, Inc., a majority-owned subsidiary of Ironwood, is an industrial biotechnology company developing and commercializing novel bioprocesses for the production of specialty chemicals. Ironwood has raised $281 million in private equity financing and is located in Cambridge, Massachusetts.

Contact:

Susan Brady

Corporate Communications

617.621.8304

sbrady@ironwoodpharma.com


'/>"/>
SOURCE Ironwood Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
3. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
4. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
5. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  Now available for sale, The Armor1 Ankle Roll ... ankle sprains by cushioning the ankle from an inversion ... the outside of any shoe type and allows the ... offering protection against sprains. With customers in physical therapy, ...
(Date:1/23/2015)... , Jan. 23, 2015   Leatt Corporation  (OTCQB: ... protective equipment for all forms of sports, including extreme ... neck brace, announced today that the UISP Lega Motociclismo ... requires all riders to wear a neck brace during ...
(Date:1/23/2015)... , January 23, 2015 Heptares Therapeutics, the ... to announce that the Malcolm Campbell Memorial Prize ... (Vice President of Chemistry), Fiona Marshall (Chief Scientific ... Officer and co-founder) for the seminal contributions to GPCR drug ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... Group -, BRISBANE, Calif., May 28 ... clinical trials program through the,initiation of an additional ... The trial will assess BSI-201, the first ADP-ribose ... for the treatment,of uterine carcinosarcoma or malignant mixed ...
... C and LymphoStat-B(R) for lupus on track for ... potential launch in 2010 -,- ABthrax(TM) for inhalation anthrax on track to begin delivery fall ... ... - GSK to advance darapladib to Phase 3 for atherosclerosis -, ROCKVILLE, ...
Cached Medicine Technology:BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer 2Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 2Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 3Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 4Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 5Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 6Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 7Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 8Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 9Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 10Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 11
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together by ... up to 30lbs in less than 12 weeks without traditional ... prompting an investigative review. , “Our Incredible Bulk review ... that allows the body to pack on a massive amount ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... A new white paper by The Beryl Institute ... long-term care environment as well as provides recommendations for ... “The Power of Person-Centeredness in Long-Term Care: A View ... patient, resident and family experience in long-term care and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... LAVAL, QC, Feb. 26 /PRNewswire-FirstCall/ - BELLUS Health Inc. ... quarter ended December 31, 2008, and commented on the ... the fourth quarter, the Company reports a net loss ... per share) for the corresponding period in the previous ...
... business unit joins the global rare disease community to ... unite patient communityCAMBRIDGE, Mass., Feb. 26 Shire Human ... the global specialty biopharmaceutical company, today announced it will ... (NORD) to celebrate World Rare Disease Day on February ...
... Autism" and Provides Important Information on Early Warning ... and Babies"R"Us stores nationwide will kick off a ... the nation,s leading organization dedicated to increasing awareness ... causes, prevention and treatments for autism; and advocating ...
... Evidence-Based Recommendations for All Levels of SocietyWASHINGTON, Feb. ... that approximately 45 percent of colon cancer cases ... the US are preventable through diet, physical activity ... for policies to reduce the global number of ...
... SANTA ANA, Calif., Feb. 26 MIND Research Institute ... of Advanced,Medical Optics (AMO), was recently elected to MIND,s ... education. He serves on numerous boards and,committees at the ... chairs the UCI,Foundation,s Board of Trustees, the Engineering Advisory ...
... of colon and breast,cancer cases in some countries are ... maintenance, according to estimates in a,report that has set ... The report, Policy and Action ... (WCRF) and American Institute for Cancer Research,(AICR), has estimated ...
Cached Medicine News:Health News:BELLUS Health reports results for the fourth quarter of 2008 2Health News:BELLUS Health reports results for the fourth quarter of 2008 3Health News:BELLUS Health reports results for the fourth quarter of 2008 4Health News:BELLUS Health reports results for the fourth quarter of 2008 5Health News:BELLUS Health reports results for the fourth quarter of 2008 6Health News:BELLUS Health reports results for the fourth quarter of 2008 7Health News:BELLUS Health reports results for the fourth quarter of 2008 8Health News:BELLUS Health reports results for the fourth quarter of 2008 9Health News:BELLUS Health reports results for the fourth quarter of 2008 10Health News:BELLUS Health reports results for the fourth quarter of 2008 11Health News:BELLUS Health reports results for the fourth quarter of 2008 12Health News:BELLUS Health reports results for the fourth quarter of 2008 13Health News:BELLUS Health reports results for the fourth quarter of 2008 14Health News:BELLUS Health reports results for the fourth quarter of 2008 15Health News:BELLUS Health reports results for the fourth quarter of 2008 16Health News:BELLUS Health reports results for the fourth quarter of 2008 17Health News:BELLUS Health reports results for the fourth quarter of 2008 18Health News:BELLUS Health reports results for the fourth quarter of 2008 19Health News:BELLUS Health reports results for the fourth quarter of 2008 20Health News:BELLUS Health reports results for the fourth quarter of 2008 21Health News:BELLUS Health reports results for the fourth quarter of 2008 22Health News:BELLUS Health reports results for the fourth quarter of 2008 23Health News:BELLUS Health reports results for the fourth quarter of 2008 24Health News:BELLUS Health reports results for the fourth quarter of 2008 25Health News:Shire Celebrates World Rare Disease Day on February 28 2Health News:Shire Celebrates World Rare Disease Day on February 28 3Health News:Shire Celebrates World Rare Disease Day on February 28 4Health News:Toys'R'Us and Babies'R'Us Launch In-Store Fundraising Campaign to Benefit Autism Speaks 2Health News:Toys'R'Us and Babies'R'Us Launch In-Store Fundraising Campaign to Benefit Autism Speaks 3Health News:Report: Many Cancers Could Be Prevented in US 2Health News:Jim Mazzo Joins MIND Research Institute's Board of Directors 2Health News:Landmark Report: Many Cancers Could be Prevented 2
Mounted on a remarkably lightweight and,flexible cotton headband with crown strap,the Sport is fully adjustable....
... putty is a product of AlloSource, ... in human tissue processing, and Interpore ... technology. InterGro combines AlloGro DBM ... to deliver a unique bone graft ...
... highest bone content (93% by volume) of ... offers excellent handling characteristics, which will enhance ... used alone or as a graft extender ... Place, The high molecular weight biocompatible carrier ...
... ICON DS Strep A is a qualitative assay ... throat swabs. The ICON DS Strep A test ... in rare and low positive colonization samples. This ... With outstanding performance, ICON DS Strep A leaves ...
Medicine Products: